Related Experiment Video
Updated: Dec 2, 2025
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
The Effect of Gemcitabine on Cell Cycle Arrest and microRNA Signatures in Pancreatic Cancer Cells
Daisuke Namima1, Shintaro Fujihara1, Hisakazu Iwama2
1Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.
Background/Aim:
Gemcitabine, an inhibitor of DNA synthesis, is the gold standard chemotherapeutic agent for pancreatic ductal adenocarcinoma (PDAC). MicroRNAs (miRNAs) play critical roles in cancers, including PDAC. However, less is known about the effect of gemcitabine on PDAC cells and miRNA expression in PDAC. We evaluated the effect of gemcitabine on the cell cycle of PDAC cells in vitro and in vivo and on the miRNA expression profile.
Materials And Methods:
Effects of gemcitabine on PK-1 and PK-9 cell growth were evaluated using a cell counting kit-8 assay. Xenografted mouse models were used to assess gemcitabine effects in vivo.
Results:
Gemcitabine inhibited the proliferation and tumour growth of PK-1 cells, and induced S phase cell cycle arrest. Numerous miRNAs were altered upon gemcitabine treatment of PK-1 cells and xenograft models.
Conclusion:
Altered miRNAs may serve as potential therapeutic targets for improving the efficacy of gemcitabine in PDAC.
Insights
Gemcitabine inhibits pancreatic ductal adenocarcinoma (PDAC) growth by halting cell division. This treatment alters microRNA (miRNA) expression, suggesting miRNAs could be future therapeutic targets for PDAC.
Area of Science:
- Molecular Oncology
- Cancer Cell Biology
- Chemotherapy Research
Background:
- Gemcitabine is a standard chemotherapy for pancreatic ductal adenocarcinoma (PDAC).
- MicroRNAs (miRNAs) are crucial in cancer development, but their role in gemcitabine-treated PDAC is unclear.
- Understanding gemcitabine's impact on PDAC cell cycle and miRNA expression is vital.
Purpose of the Study:
- To investigate the effects of gemcitabine on PDAC cell cycle progression.
- To analyze changes in miRNA expression profiles following gemcitabine treatment in PDAC.
- To explore potential therapeutic targets for enhancing gemcitabine efficacy.
Main Methods:
- In vitro assessment of gemcitabine's impact on PK-1 and PK-9 cell proliferation using a cell counting kit-8 assay.
- In vivo evaluation of gemcitabine's efficacy in xenografted mouse models.
- Comprehensive analysis of miRNA expression profiles after gemcitabine treatment.
Main Results:
- Gemcitabine significantly inhibited PK-1 cell proliferation and tumor growth.
- Gemcitabine induced cell cycle arrest at the S phase in PDAC cells.
- Gemcitabine treatment led to significant alterations in numerous miRNAs in both cell lines and xenograft models.
Conclusions:
- Gemcitabine effectively suppresses PDAC growth and alters miRNA expression.
- The identified miRNA changes represent potential biomarkers and therapeutic targets.
- Targeting altered miRNAs could enhance gemcitabine's effectiveness in treating PDAC.
Related Concept Videos
02:34Inhibition of Cdk Activity
01:15Drugs that Stabilize Microtubules